Hypertriglyceridemia omega-3 fatty acids: Difference between revisions

Lipoprotein Disorders Main Page
	Hyperlipoproteinemia Microchapters
Hypercholesterolemia Patient Information
Hypertriglyceridemia Patient Information
Overview
Classification Familial hyperchylomicronemia Familial hypercholesterolemia Familial combined hyperlipidemia Dysbetalipoproteinemia Primary hypertriglyceridemia Mixed hyperlipoproteinemia
Differential Diagnosis
Screening
ACC/AHA Guideline Recommendations
Summary
Treatment
Major recommendations for statin therapy
Therapeutic response to statin therapy
Blood cholesterol LDL and non-HDL treatment goals
Treatment in heart failure and hemodialysis
Primary prevention
Secondary prevention
Intensity of statin therapy in primary and secondary prevention
Safety Recommendations
Guideline on Lifestyle Management

VisualWikitext

Latest revision as of 19:58, 23 November 2016

For full Omega-3 fatty acid drug info click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]

Overview

Treatment of hypertriglyceridemia is by restriction of carbohydrates and fat in the diet, as well as with niacin, fibrates and statins (three classes of drugs). Increased fish oil intake may substantially lower an individual's triglycerides.^[1]^[2]^[3].

Trial Supportive Data

Study name	Source & year	Study question	Study Design	Study Population	Time period	Intervention	Results	Conclusions
Effect of combination of Omega-3 fatty acid and Simvastatin on hypertriglyceridemia ^[4]	Heart, 2001	To access the safety and efficacy of Omega-3 fatty acid and Simvastatin on hypertriglyceridemia	Double blinded randomized controlled trial	59 patients with CHD, on simvastatin 10-40 mg/d, with serum triglycerides > 2.3 mmol/l	1 year	Omacor (84% omega-3 fatty acid) 2 g BD or placebo	Decrease in serum triglycerides by 20-30% (p<0.005) Decrease in very low-density lipoprotein (VLDL) cholesterol by 30-40% (p<0.005)	Omacor combination with simvastatin was found to be a safe and effective in decreasing serum triglycerides in coronary heart disease

Researchers say diets rich in Omega-3 fatty acids can help people with heart disease live longer, but why these oils are so beneficial remains unclear. A new study looks at how higher fish oil levels in the blood may protect the caps on chromosomes, which help measure biological aging

External Links

http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=184

References

↑ "Lipids Online Slides: hypertriglyceridemia, ICAM-1, fish oil, E-selectin".
↑ Terres W, Beil U, Reimann B, Tiede S, Bleifeld W (1991). "[Low-dose fish oil in primary hypertriglyceridemia. A randomized placebo-controlled study]". Zeitschrift für Kardiologie (in German). 80 (1): 20–4. PMID 2035283.
↑ "Fish oils in hypertriglyceridemia - Fish Oils Revisited Nutrition Research Newsletter - Find Articles".
↑ Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA; et al. (2001). "An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia". Heart. 85 (5): 544–8. PMC 1729738. PMID 11303007.

Template:WikiDoc Sources

[1] "Lipids Online Slides: hypertriglyceridemia, ICAM-1, fish oil, E-selectin".

[pmid2035283-2] Terres W, Beil U, Reimann B, Tiede S, Bleifeld W (1991). "[Low-dose fish oil in primary hypertriglyceridemia. A randomized placebo-controlled study]". Zeitschrift für Kardiologie (in German). 80 (1): 20–4. PMID 2035283.

[3] "Fish oils in hypertriglyceridemia - Fish Oils Revisited Nutrition Research Newsletter - Find Articles".

[pmid11303007-4] Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA; et al. (2001). "An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia". Heart. 85 (5): 544–8. PMC 1729738. PMID 11303007.

[1]

[2]

[3]

[4]

@@ Line 1: / Line 1: @@
-{{Hypertriglyceridemia}}
+__NOTOC__
+{{Hyperlipoproteinemia}}
 '''For full Omega-3 fatty acid drug info click [[Omega-3 fatty acid|here]]'''
-{{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh@perfuse.org]
+{{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com]
 ==Overview==
 Treatment of hypertriglyceridemia is by restriction of carbohydrates and fat in the [[diet (nutrition)|diet]], as well as with [[niacin]], [[fibrate]]s and [[statin]]s (three classes of drugs).  Increased [[fish oil]] intake may substantially lower an individual's triglycerides.<ref>{{cite web |url=http://www.lipidsonline.org/slides/slide01.cfm?q=hypertriglyceridemia&dpg=13 |title=Lipids Online Slides: hypertriglyceridemia, ICAM-1, fish oil, E-selectin | format= |work=}}</ref><ref name="pmid2035283">{{cite journal |author=Terres W, Beil U, Reimann B, Tiede S, Bleifeld W |title=[Low-dose fish oil in primary hypertriglyceridemia. A randomized placebo-controlled study] |language=German |journal=Zeitschrift für Kardiologie |volume=80 |issue=1 |pages=20-4 |year=1991 |pmid=2035283 |doi=}}</ref><ref>{{cite web |url=http://www.findarticles.com/p/articles/mi_m0887/is_n4_v9/ai_8960077 |title=Fish oils in hypertriglyceridemia - Fish Oils Revisited Nutrition Research Newsletter - Find Articles |format= |work=}}</ref>.
-==Omega-3 fatty acids==
+===Trial Supportive Data===
-===Mechanism of benefit===
-* Decreased hepatic [[lipogenesis]]
+{|border="1" align="center" style="background:light gray"
-* Increased plasma [[lipoprotein lipase]] activity.
+|-
-* Increased hepatic mitochondrial and peroxisomal [[beta-oxidation]]
+| bgcolor="Gray" |'''Study name'''
-* Inhibition of acyl CoA:1,2-[[diacylglycerol acyltransferase]] enzyme
+| bgcolor="Gray" |'''Source & year'''
-* [[Omega-3 fatty acid]]s component EPA and DHA are poor enzyme substrates for triglyceride synthesis in the liver
+| bgcolor="Gray" |'''Study question'''
-* EPA and DHA inhibits esterification of other fatty acids.
+| bgcolor="Gray" |'''Study Design'''
-===Side-effects===
+| bgcolor="Gray" |'''Study Population'''
-* Dose dependent gastrointestinal side-effects like nausea (approximately 4 % of individuals at < 3 gm/d, and 20% at >4gm/d.
+| bgcolor="Gray" |'''Time period'''
-* The peculiar fishy smell can be a reason for discontinuation among many patients. This can be reduced by
+| bgcolor="Gray" |'''Intervention'''
-** Freezing of medication
+| bgcolor="Gray" |'''Results'''
-** Trying different medication prepration
+| bgcolor="Gray" |'''Conclusions'''
-** Taking drugs with food
+|-
-* Increased incidences of bleeding at high doses (According to FDA total intakes up to 3 g per day of EPA and DHA comes under the category of Generally Recognized As Safe (GRAS)
+| Effect of combination of Omega-3 fatty acid and Simvastatin on hypertriglyceridemia <ref name="pmid11303007">{{cite journal| author=Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA et al.| title=An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. | journal=Heart | year= 2001 | volume= 85 | issue= 5 | pages= 544-8 | pmid=11303007 | doi= | pmc=PMC1729738 | url= }} </ref>
+| Heart, 2001
+| To access the safety and efficacy of Omega-3 fatty acid and Simvastatin on hypertriglyceridemia
+| Double blinded randomized controlled trial
+| 59 patients with CHD, on simvastatin 10-40 mg/d, with serum triglycerides > 2.3 mmol/l
+| 1 year
+| Omacor (84% omega-3 fatty acid) 2 g BD or placebo
+|
+*Decrease in serum [[triglycerides]] by 20-30% (p<0.005)
+*Decrease in very low-density lipoprotein ([[VLDL]]) cholesterol by 30-40% (p<0.005)
+|
+* [[Omacor]] combination with [[simvastatin]] was found to be a safe and effective in decreasing serum [[triglycerides]] in [[coronary heart disease]]
+|-
+|}
+{{#ev:youtube|9l94Nm241GI}}
+===Researchers say diets rich in Omega-3 fatty acids can help people with heart disease live longer, but why these oils are so beneficial remains unclear. A new study looks at how higher fish oil levels in the blood may protect the caps on chromosomes, which help measure biological aging===
+==External Links==
+http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=184
 ==References==
 {{Reflist|2}}
-[[fr:Hypertriglycéridémie]]
+{{Lipopedia}}
-[[pt:Hipertrigliceridemia]]
+[[Category:Lipopedia]]
 [[Category:Cardiology]]
 [[Category:Dermatology]]

v t e Lipopedia
Basic Science	Cholesterol • Triglyceride Lipoprotein metabolism and transport Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X Apolipoprotein: APOA (1, 2, 4, 5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a) Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1 Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1
Lipoprotein Disorders	Lipoprotein disorders Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V) Secondary lipoprotein disorders
Abnormal Laboratory Lipid Profile	Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL